CD23 (E1R4G) Rabbit mAb (BSA and Azide Free) #89186
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | |
| Source/Isotype | Rabbit IgG |
Application Key:
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
Formulation
Storage
Specificity / Sensitivity
CD23 (E1R4G) Rabbit mAb (BSA and Azide Free) recognizes endogenous levels of total CD23 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala118 of human CD23 protein.
Background
CD23, also known as FcεRII, is a trimeric type II transmembrane glycoprotein member of the calcium-dependent (C-type) lectin family (1). CD23 is expressed in B and T lymphocytes, monocytes, polymorphonuclear leukocytes, follicular dendritic cells, intestinal epithelial cells, and bone marrow stromal cells (2-8). CD23 was first identified as a low-affinity receptor for IgE and the engagement of membrane bound CD23 leads to suppressed IgE production by B lymphocytes (9). CD23 can be cleaved to form a soluble protein which can drive cytokine release in monocytic cells, nitric oxide (NO) production, and the synthesis of cyclic adenosine 3′5′-monophosphate (cAMP) (10). Soluble CD23 signals through integrins, activating MAPK and NF-κB pathways (11). CD23 is a useful marker in the prognosis of neoplastic disease, is elevated in a variety of autoimmune and inflammatory conditions, and is being investigated as a therapeutic target for IgE-mediated allergy, arthritis, and B cell chronic lymphocytic leukemia (CLL) (12).
- Wurzburg, B.A. et al. (2006) Structure 14, 1049-58.
- Armitage, R.J. et al. (1989) Eur J Immunol 19, 31-5.
- Vercelli, D. et al. (1988) J Exp Med 167, 1406-16.
- Yamaoka, K.A. et al. (1996) Int Immunol 8, 479-90.
- Capron, M. et al. (1992) Immunol Res 11, 252-9.
- Rieber, E.P. et al. (1993) Adv Exp Med Biol 329, 393-8.
- Yu, L.C. et al. (2003) Am J Physiol Gastrointest Liver Physiol 285, G223-34.
- Fourcade, C. et al. (1992) Eur Cytokine Netw 3, 539-43.
- Suter, U. et al. (1987) Nucleic Acids Res 15, 7295-308.
- Rezzonico, R. et al. (2001) Blood 97, 2932-40.
- Rezzonico, R. et al. (2000) Blood 95, 3868-77.
- Acharya, M. et al. (2010) Clin Exp Immunol 162, 12-23.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.